Difference between revisions of "Oxaliplatin (Eloxatin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 9: Line 9:
 
*[[Cholangiocarcinoma]]
 
*[[Cholangiocarcinoma]]
 
*[[Chronic lymphocytic leukemia]]
 
*[[Chronic lymphocytic leukemia]]
−
*[[Colon cancer]] ‎
+
*[[Colorectal cancer]]
 +
**[[Colon cancer]]
 +
**[[Rectal cancer]]
 
*[[Diffuse large B-cell lymphoma]]
 
*[[Diffuse large B-cell lymphoma]]
 
*[[Esophageal cancer]]
 
*[[Esophageal cancer]]
 +
**[[Esophageal adenocarcinoma]]
 
*[[Extranodal NK- and T-cell lymphoma, nasal type]]
 
*[[Extranodal NK- and T-cell lymphoma, nasal type]]
 
*[[Gallbladder cancer]]
 
*[[Gallbladder cancer]]
Line 20: Line 23:
 
*[[Nasopharyngeal carcinoma]]
 
*[[Nasopharyngeal carcinoma]]
 
*[[Pancreatic cancer]]
 
*[[Pancreatic cancer]]
−
*[[Rectal cancer]]
 
 
*[[Testicular cancer]]
 
*[[Testicular cancer]]
 
*[[Transformed lymphoma]]
 
*[[Transformed lymphoma]]
Line 30: Line 32:
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
* 8/9/2002: Initial accelerated approval in combination with infusional [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]], is indicated for the treatment of patients with metastatic carcinoma of the [[Colon cancer | colon]] or [[Rectal cancer | rectum]] whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]] and [[Irinotecan (Camptosar) | irinotecan]].
+
===[[Colon cancer]]===
−
* 1/9/2004: Converted to regular approval in combination with infusional [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]], is indicated for the treatment of advanced carcinoma of the [[Colon cancer | colon]] or [[Rectal cancer | rectum]].
 
 
* 11/4/2004: New indication: "used in combination with infusional [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]], is indicated for adjuvant treatment of stage III [[Colon cancer | colon cancer]] patients who have undergone complete resection of the primary tumor.
 
* 11/4/2004: New indication: "used in combination with infusional [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]], is indicated for adjuvant treatment of stage III [[Colon cancer | colon cancer]] patients who have undergone complete resection of the primary tumor.
 +
 +
===[[Colorectal cancer]]===
 +
* 8/9/2002: Initial accelerated approval in combination with infusional [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]], is indicated for the treatment of patients with metastatic [[Colorectal cancer|carcinoma of the colon or rectum]] whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]] and [[Irinotecan (Camptosar) | irinotecan]].
 +
* 1/9/2004: Converted to regular approval in combination with infusional [[Fluorouracil (5-FU) | 5-FU]]/[[Folinic acid (Leucovorin) | LV]], is indicated for the treatment of advanced [[Colorectal cancer|carcinoma of the colon or rectum]].
  
 
==Also known as==
 
==Also known as==
Line 48: Line 53:
 
[[Category:Chronic lymphocytic leukemia medications]]
 
[[Category:Chronic lymphocytic leukemia medications]]
 
[[Category:Colon cancer medications]]
 
[[Category:Colon cancer medications]]
 +
[[Category:Colorectal cancer medications]]
 
[[Category:Diffuse large B-cell lymphoma medications]]
 
[[Category:Diffuse large B-cell lymphoma medications]]
 +
[[Category:Esophageal adenocarcinoma medications]]
 
[[Category:Esophageal cancer medications]]
 
[[Category:Esophageal cancer medications]]
 
[[Category:Extranodal NK- and T-cell lymphoma, nasal type medications]]
 
[[Category:Extranodal NK- and T-cell lymphoma, nasal type medications]]

Revision as of 01:57, 1 May 2022

General information

Class/mechanism: Platinum analog, alkylating-like, which produces interstrand and intrastrand DNA crosslinks that inhibit DNA replication and transcription, causing non-cell cycle specific cytotoxicity and death.[1][2][3]
Route: IV
Extravasation: irritant (usually), vesicant (rare)

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Colon cancer

  • 11/4/2004: New indication: "used in combination with infusional 5-FU/ LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.

Colorectal cancer

Also known as

  • Code names: JM-83, RP-54780, SR-96669
  • Brand names: Coxatin, Curaplat, Cure-X, Dacotin, Dacplat, Eloplat, Eloxatin, Eloxatine, Oplatin, OxaLitin, Oxiplat, Oxitan, Oxzucia, Sibatin, Xaloplat, Xylotin, X-Plat, Zildox

References

  1. ↑ 1.0 1.1 1.2 Oxaliplatin (Eloxatin) package insert
  2. ↑ Oxaliplatin (Eloxatin) package insert (locally hosted backup)
  3. ↑ Eloxatin manufacturer's website
  4. ↑ Oxaliplatin (Eloxatin) patient drug information (Chemocare)
  5. ↑ Oxaliplatin (Eloxatin) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Oxaliplatin_(Eloxatin)&oldid=56053"